[The use of tardyferon in the combined treatment of patients with chronic atrophic gastritis and peptic ulcer complicated by hemorrhage].
Tardipherone is capable of maximum absorption in the initial portion of small intestine, iron being in its retarding form, which fact ensures a prolonged action of the drug, mucoprotease being a part of tardipherone composition acting to guard gastric and duodenal mucosae against irritating effect of iron. Tardipherone was found to be efficacious in treating patients with ulcer disease complicated by bleeding. Under its effect the hemogram indices get normalized as does the ratio of aggressive to protective factors of gastric juice, which factors play a major part in the emergent relapse of the illness. The use of tardipherone was found to be justified in the treatment of patients with chronic atrophic gastritis, being associated with gratifying shifts in the clinical picture of the condition and improvement in the hemogram characteristics.
Kharchenko
N V
NV
Degtiareva
I I
II
Rodonezhskaia
E V
EV
Levin
I V
IV
D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000150:complications*; D005260:Female; D005296:Ferrous Compounds / Q000627:therapeutic use*; D005757:Gastritis, Atrophic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000627:therapeutic use*; D010438:Peptic Ulcer Hemorrhage / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D012074:Remission Induction; D013276:Stomach Ulcer / Q000150:complications*
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005296:Ferrous Compounds; D009077:Mucins; C009380:ferrous sulfate, mucin drug combination